Recherches "plusieurs pathologies" AcSé Pembrolizumab Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types. Saint-Cloud CAROLE SOUSSAIN
Recherches "plusieurs pathologies" AcSé Vemurafenib Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Saint-Cloud ETIENNE BRAIN
Pédiatrie Tumeurs solides eSMART European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors. Paris ISABELLE AERTS
Recherches "plusieurs pathologies" SUMMIT- PUMA-NER-0502 An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification. Saint-Cloud FRANCOIS-CLEMENT BIDARD
Sein métastatique RH+ CONTESSA - ODO-TE-B301 Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane Saint-Cloud ETIENNE BRAIN
Hématologie Myélodysplasie QPL-MDS Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) Saint-Cloud SANDRA MALAK
Gynécologie - Col utérus MK3475-826 (Keynote-826) A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826) Saint-Cloud
Recherches "plusieurs pathologies" DERMACLIC (IC 2019-12) Study on skin toxicities induced by cancer treatments Paris
Sein métastatique RH+ DOLAF An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib Saint-Cloud
Recherches "plusieurs pathologies" MCLA-128-CL01 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Saint-Cloud